{"entity":{"id":"nct05745623","kind":"trial","name":"Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors","aka":[],"tldr":"A phase 1/2 trial of ICP-723 in brain and spinal cord tumours, run by Beijing InnoCare Pharma Tech Co., Ltd., now recruiting.","summary":"Study of ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors is a phase 1/2 interventional study registered as NCT05745623 by Beijing InnoCare Pharma Tech Co., Ltd., with 70 participants planned, started 2022-12-27 and due to reach its primary completion in 2027-12-25. Interventions recorded: ICP-723.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05745623","url":"https://clinicaltrials.gov/study/NCT05745623"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["brain-tumours"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05745623","phase":"1/2","setting":"A Multi-center, Non-Randomized, Open-Label Phase 2 Basket Clinical Trial to Evaluate ICP-723 in Patients With Advanced Solid Tumors or Primary Central Nervous System Tumors","sponsor":"Beijing InnoCare Pharma Tech Co., Ltd.","enrolled":70,"outcomes":[]},"route":"/trials/nct05745623/","neighbours":{"cancer":[{"id":"brain-tumours","kind":"cancer","name":"Brain and spinal cord tumours (all types)","route":"/cancers/brain-tumours/"}]}}